Endotoxin pp 537-547 | Cite as

Various Aspects of Synergism between Endotoxin and MDPs

  • M. Parant
  • L. Chedid
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 256)

Abstract

Muramyl dipeptide (MDP) is a synthetic glycopeptide analog of a part of bacterial peptidoglycan (13). It represents the minimal adjuvant-active structure and has also been shown to stimulate nonspecific resistance in animals subsequently infected (9). These effects have been demonstrated after injecting MDP in saline by different routes. The synthesis of MDP was followed by the preparation of a large number of derivatives with the hope of determining structure-activity relationships (12, 15), or at least of selecting immunostimulating compounds, which did not retain several side effects inherent to MDP administration (6, 24). Such an evaluation has allowed us to select an MDP derivative called Murabutide which is undergoing clinical trials with conventional vaccines after its safety has been established by animal toxicological studies, and in a phase I clinical trial.

Keywords

Toxicity Sarcoma Pseudomonas Acne Pertussis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bauss, F., Dröge, W. and M’dnnel, D. N., 1985, Tumor necrosis factor mediates endotoxic effects in mice. Infect. Immun. 55: 1622.Google Scholar
  2. 2.
    Beutler, B., Milsark, I. W. and Cerami, A. C., 1985, Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869.Google Scholar
  3. 3.
    Bloksma, N., Hofhuis, F. M. and Willers, J. M., 1984, Endotoxin-induced antitumor activity in the mouse is highly potentiated by muramyl dipeptide. Cancer Letters 23: 159.Google Scholar
  4. 4.
    Bloksma, N., Hof huis, F. M. and Willers, J. M., 1984, Muramyl dipeptide is a powerful potentiator of the antitumor action of various tumor necrotizing agents. Cancer Immunol. Immunother. 17: 154.Google Scholar
  5. 5.
    Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N. and Williamson, B., 1975, An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666.Google Scholar
  6. 6.
    Chedid, L., 1983, Muramyl peptides as possible endogenous immunopharmacological mediators. Microbiol. Immun. 27: 723.Google Scholar
  7. 7.
    Chedid, L., Audibert, F., Bona, C., Damais, C., Parant, F. and Parant, M., 1975, Biological activities of endotoxin detoxified by alkylation. Infect. Immun. 12: 714.Google Scholar
  8. 8.
    Chedid, L., Parant, M., Audibert, F., Riveau, G., Parant, F., Lederer, E., Choay, J. and Lefrancier, P., 1982, Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect. Immun. 35: 417.Google Scholar
  9. 9.
    Chedid, L., Parant, M., Parant, F., Lefrancier, P., Choay, J. and Lederer, E.,, 1977, Enhancement of non-specific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetyl-muramyl-Lalanyl-D-isoglutamine) and several analogs. Proc. Natl. Acad. Sci. USA 74: 2089.Google Scholar
  10. 10.
    Chedid, L., Parant, M., Parant, F., Audibert, F., Lefrancier, P., Choay, J. and Sela, M., 1979, Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DLalanyl)-poly(L-lysine) carrier. Proc. Natl. Acad. Sci. USA 76: 6557.Google Scholar
  11. 11.
    Havell, E. A., 1987, Production of tumor necrosis factor during murine Listeriosis. J. Immunol. 139: 4225.Google Scholar
  12. 12.
    Kotani, S., Takeda, H., Tsujimoto, M., Ogawa, T., Mori, Y., Koga, T., Iribe, H., Tanaka, A., Nagao, S., McGhee, J. R., Michalek, S. M., Kawata, S., Shiba, T. and Kusumoto, S., 1983, Lipophilic muramyl peptides and synthetic lipid A analogs as immunomodulators, in: “Progress in Immunology V,” Y. Yamamura and T. Tada, eds., Academic Press, Japan.Google Scholar
  13. 13.
    Lederer, E., 1980, Syntheric immunostimulants derived from the bacterial cell wall. J. Med. Chem. 23: 819.Google Scholar
  14. 14.
    Lefrancier, P., Derrien, M., Jamet, X., Choay, J.-, Lederer, E., Audibert, F., Parant, F., Parant, M. and Chedid, L., 1982, Apyrogenic adjuvant-active N-acetylmuramyl dipeptides. J. Med. Chem. 25: 87.Google Scholar
  15. 15.
    Lefrancier, P. and Lederer, E., 1981, Chemistry of synthetic immunomodulant muramyl peptides. Prog. Chem. Org. Nat. Prod. 40: 1.Google Scholar
  16. 16.
    Lehmann, V., Freudenberg, M. A. and Galanos, C., 1987, Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and Dgalactosamine-treated mice. J. Exp. Med. 165: 657.Google Scholar
  17. 17.
    Level, M., Bernard, J. M., Lefrancier, P. and Phillips, N., 1984, New lipophilic muramyl dipeptide derivatives: synthesis and biological activity of their liposome encapsulated formulation, in: “Forum Peptides,” B. Castro and J. Martinez, eds., Centre de Pharmacologie, Montpellier, France, p. 250.Google Scholar
  18. 18.
    Mönnel, D., Meltzer, M. S. and Mergenhagen, S. E., 1980, Generation and characterization of a lipopolysaccharide-induced and serum-derived factor for tumor cells. Infect. Immun. 28: 204.Google Scholar
  19. 19.
    Niitsu, Y., Watanabe, N., Sone, H., Neda, H. and Urushizaki, I., 1985, T cell involvement in production of tumor necrosis factor: reconstitution experiment with nude mice. Japanese J. Cancer Res. 76: 395.Google Scholar
  20. 20.
    Old. L. J., 1976, Tumor necrosis factor. Clin. Bull. 6: 118.Google Scholar
  21. 21.
    Palladino, M. A., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., Deleo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., Liggitt, D. and Patton, J. S., 1987, Characterization of the antitumor activities of human tumor necrosis factor-a and the comparison with other cytokines: induction of tumor specific immunity. J. Immunol. 138: 4023.Google Scholar
  22. 22.
    Parant, M., 1983, Effect of LPS on nonspecific resistance to bacterial infections, in: “Beneficial Effects of Endotoxins,” A. Nowotny, ed.. Plenum Press, New York, p. 179.Google Scholar
  23. 23.
    Parant, M., 1988, Role of tumor necrosis factor in nonspecific stimulation of the mouse resistance to infections, in: “Tumor Necrosis Factor/Cachectin, Lymphotoxins and Related Cytokines,” H. Kirchner and B. Bonavida, eds., Karger, Basel, p. 234.Google Scholar
  24. 24.
    Parant. M. and Chedid, L., 1984, Stimulation of nonspecific resistance to infections by synthetic immunoregulatory agents. Infection 12: 230.Google Scholar
  25. 25.
    Parant, M. and Chedid, L., 1987, Muramyl dipeptides, host immunity and enhancement, in: “Antibiosis and Host Immunity,” A. Szentivanyi, H. Friedman and G. Gillissen, eds., Plenum Press, New York, p. 291.Google Scholar
  26. 26.
    Parant, M., Parant, F. and Chedid, L., 1978, Enhancement of the neonate’s non specific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc. Natl. Acad. Sci. USA 75: 3395.Google Scholar
  27. 27.
    Parant, M., Parant, F., Vinit, M. A. and Chedid. L., 1987, Action protectrice du tumor necrosis factor (TNF) obtenu par recombinaison gönötique contre l’infection expörimentale bactörienne et fongique. C. R. Acad. Sci. Paris 304: 1.Google Scholar
  28. 28.
    Ribi, E. E., Cantrell, J. L., VonEschen, K. B. and Schwartzman, S. M., 1979, Enhancement of endotoxic shock by N-acetyl-L-alanyl-(L- seryl)-Disoglutamine (muramyl dipeptide), Cancer Res. 39: 4756.Google Scholar
  29. 29.
    Ribi, E., Parker, R., Strain, S. M., Mizuno, Y., Nowotny, A., VonEschen, K. B., Cantrell, J. L., McLaughlin, C. A., Hwang, K. M. and Goren, M. B., 1979, Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins. Cancer Immunol. Immunother. 7: 43.Google Scholar
  30. 30.
    Rothstein, J. L. and Schreiber, H., 1988, Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc. Natl. Acad. Sci. USA 85: 607.Google Scholar
  31. 31.
    Ruff, M. R. and Gifford, G. E., 1981, Tumor necrosis factor, in: “Lymphokines Vol. 2,” E. Pick, ed., Academic Press, New York, p. 235.Google Scholar
  32. 32.
    Tracey. K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., Zentella, A., Albert, J. D.. Shires, G. T, and Cerami, A.. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234: 470.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • M. Parant
    • 1
  • L. Chedid
    • 2
  1. 1.Laboratory of Experimental ImmunopharmacologyInstitut Biomédical des CordeliersParisFrance
  2. 2.University of South FloridaTampaUSA

Personalised recommendations